Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3

Detalles Bibliográficos
Autores principales: Powderly, John, Cote, Gregory, Flaherty, Keith, Szmulewitz, Russell Z, Ribas, Antoni, Weber, Jeffrey, Loo, Deryk, Baughman, Jan, Chen, Francine, Moore, Paul, Bonvini, Ezio, Vasselli, James, Wigginton, Jon, Cohen, Roger, Burris, Howard, Chmielowski, Bartosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Oral Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645418/
http://dx.doi.org/10.1186/2051-1426-3-S2-O8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645418/
http://dx.doi.org/10.1186/2051-1426-3-S2-O8

Ejemplares similares